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PERCH SitE RESultS
Background: Pneumonia remains the leading cause of death in young 
children globally. The changing epidemiology of pneumonia requires up-
to-date data to guide both case management and prevention programs. 
The Gambia study site contributed a high child mortality, high pneumonia 
incidence, low HIV prevalence, Haemophilus influenzae type b and pneu-
mococcal conjugate vaccines-vaccinated rural West African setting to the 
Pneumonia Etiology Research for Child Health (PERCH) Study.
Methods: The PERCH study was a 7-country case-control study of the 
etiology of hospitalized severe pneumonia in children 1–59 months of age 
in low and middle-income countries. Culture and nucleic acid detection 
methods were used to test nasopharyngeal/oropharyngeal swabs, blood, 
induced sputum and, in selected cases, lung or pleural fluid aspirates. Eti-
ology was determined by integrating case and control data from multiple 
specimens using the PERCH integrated analysis based on Bayesian proba-
bilistic methods.
Results: At The Gambia study site, 638 cases of World Health Organization-
defined severe and very severe pneumonia (286 of which were chest radio-
graph [CXR]-positive and HIV-negative) and 654 age-frequency matched 
controls were enrolled. Viral causes predominated overall (viral 58% vs. 
bacterial 28%), and of CXR-positive cases respiratory syncytial virus (RSV) 
accounted for 37%, Streptococcus pneumoniae 13% and parainfluenza was 
responsible for 9%. Nevertheless, among very severe cases bacterial causes 
dominated (77% bacterial vs. 11% viral), led by S. pneumoniae (41%); 
Mycobacterium tuberculosis, not included in “bacterial”, accounted for 9%. 
93% and 80% of controls ≥1 year of age were, respectively, fully vaccinated 
for age against Haemophilus influenzae and S. pneumoniae.
Conclusions: Viral causes, notably RSV, predominated in The Gambia 
overall, but bacterial causes dominated the severest cases. Efforts must 
continue to prevent disease by optimizing access to existing vaccines, and 
to develop new vaccines, notably against RSV. A continued emphasis on 
appropriate case management of severe pneumonia remains important.
Key Words: Gambia, pneumonia, etiology, childhood, Pneumonia Etiology 
Research for Child Health
(Pediatr Infect Dis J 2021;40:S7–S17)
Pneumonia is the biggest single cause of death in children globally, accounting for 15% of 5.3 million deaths in chil-
dren under the age of 5 years in 2018.1 A progress has been made 
in the reduction of pneumonia morbidity and mortality, but to 
reach the United Nations Sustainable Development Goal tar-
gets for child health, deaths and morbidity from pneumonia will 
need to be substantially further reduced.2 The epidemiology and 
etiology of pneumonia are changing as a result of global trends 
strongly influenced by social development and vaccination, prin-
cipally the roll out of conjugate Haemophilus influenzae type b 
(Hib) and pneumococcal conjugate vaccines (PCV). It is in this 
context that the Pneumonia Etiology Research for Child Health 
(PERCH) study has been undertaken to contribute to global 
pneumonia control efforts for the 21st century. PERCH is a 
7-country, 9-site study of childhood pneumonia in 5 countries in 
Africa (The Gambia, Mali, Kenya, Zambia and South Africa) and 
2 countries in Asia (Thailand and Bangladesh).3 The overwhelm-
ing burden of death and sickness from pneumonia occurs in such 
low and middle-income countries (LMICs). Specifically, half of 
childhood deaths from pneumonia occur in sub-Saharan Africa.4 
The Gambia, like other countries in this region, suffers a high toll 
from pneumonia, and this report details the etiology of childhood 
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pneumonia in this West African nation with high PCV and Hib 
vaccine coverage.5–9
STUDY POPULATION AND METHODS
The Gambia, in West Africa, is a resource-poor country with 
a population of 1.8 million, high child mortality (74 children under 
5 per 1000 live births [2012]), low HIV prevalence (<2%) and sea-
sonal malaria transmission.10, 11 The Gambia is located within the 
semiarid Sahel region of sub-Saharan Africa and extends some 400 
km inland from the Atlantic coast of West Africa. Childhood pneu-
monia etiology in The Gambia has been historically dominated 
by Streptococcus pneumoniae and H. influenzae, vaccinations for 
which were introduced in 2009 and 1997 (for Hib), respectively.12, 
13 The PERCH study site in The Gambia was located in the rural 
Upper River Region within an area covered by the Basse Health 
and Demographic Surveillance System (BHDSS),14 which is host 
to ongoing health research including pneumococcal surveillance.15 
The BHDSS has a population of 178,510 (2014), of which 32,530 
(18%) are children under 5 years of age; all births, deaths, pregnan-
cies and migration into and out of the surveillance area are enumer-
ated 3 times a year. The only major health center in the area is the 
Basse Health Centre, located in Basse township, and the area is also 
served by several subsidiary smaller health facilities (Supplement 
Digital Content 1, http://links.lww.com/INF/D996). The Basse site 
provides the PERCH study representation of a rural, low-HIV-sero-
prevalence, African setting with seasonal malaria transmission.
Selection of Participants
We conducted a case-control study comparing severe hospi-
talized pneumonia cases with community controls. Details of entry 
criteria for the PERCH study have been described.3,16 Cases were chil-
dren 1–59 months of age with severe pneumonia who presented to 
government health centers within the BHDSS (Basse, Dembakunda, 
Garawol and Fatoto Health Centers) between November 3, 2011 and 
November 2, 2013. We enrolled patients 7 days per week between the 
hours of 8 am and 6 pm. We defined severe pneumonia using modi-
fied World Health Organization (WHO) criteria (2005 definitions),17 
namely cough or difficulty in breathing, plus “danger signs” to define 
very severe pneumonia (danger signs comprising central cyanosis, 
difficulty breast-feeding/drinking, vomiting everything, multiple or 
prolonged convulsions, lethargy/unconsciousness or head nodding), 
or lower chest wall indrawing in the absence of danger signs to define 
severe pneumonia.16, 18 We excluded children with wheezing if their 
lower chest wall indrawing resolved after standardized bronchodila-
tor therapy. Radiologic pneumonia was defined using WHO crite-
ria applied in a standardized interpretation process.19,20 Cases were 
defined as chest radiograph (CXR)-positive if they had either clear 
consolidation meeting WHO primary endpoint (PEP) criteria or 
“other infiltrates” not meeting PEP criteria.
Controls comprised children from the community 1–59 
months of age randomly selected from within the BHDSS. Poten-
tial controls were visited in the community and invited to partic-
ipate, and those giving informed consent were brought to Basse 
Health Centre for enrollment procedures. Controls were frequency-
matched on age with the goal of a minimum enrollment of 25 con-
trols per month. Those meeting the case definitions for PERCH 
were excluded, but those with mild acute respiratory infections 
were not.
Clinical Samples Collected and Laboratory 
Analyses Undertaken
Details of clinical samples collected and laboratory testing 
have been published and are summarized in Supplemental Digital 
Content 2, http://links.lww.com/INF/D997.21–23 In summary, from 
all participants, we collected nasopharyngeal and oropharyngeal 
(NP/OP) swabs for polymerase chain reaction (PCR) for respira-
tory pathogens (FTD Resp-33 kit; Fast-track Diagnostics, Sliema, 
Malta) and culture (plus serotyping) for pneumococcus, blood for 
pneumococcal PCR and serum for antibiotic activity testing. From 
cases, we also collected blood for bacterial culture, HIV testing and 
malaria parasites, induced sputum for bacterial culture and PCR for 
respiratory pathogens, gastric aspirates for Mycobacterium tuber-
culosis microscopy and culture in selected cases, and in selected 
cases meeting strict criteria, we undertook transthoracic percutane-
ous direct fine needle aspiration of the pneumonia lesion. For PCR, 
positivity was defined using quantitative PCR density thresholds 
when that improved distinction between cases and controls, which 
was the case for the following pathogens with poor specificity (ie, 
odds ratio [OR] < 1): S. pneumoniae, H. influenzae, cytomegalovi-
rus (CMV) and Pneumocystis jirovecii from NP/OP and S. pneumo-
niae from whole blood.24–26
Statistical Analysis and Data Management
Data were entered, cross-checked and validated using a 
purpose-built online data management system designed by The 
Emmes Corporation (Rockville, MD).27 Simple descriptive analy-
ses were used to describe the frequency and prevalence of patho-
gens identified by specific laboratory tests stratified by a range of 
variables; for specimen results available from cases and controls, 
ORs, adjusted for age and detection of other pathogens were also 
calculated. Comparisons between groups were made for categorical 
variables using logistic regression adjusted for age.
The proportion of pneumonia due to each pathogen was esti-
mated using the PERCH integrated analysis (PIA) method, which 
is described in detail elsewhere.28–30 In brief, the PIA is a Bayes-
ian nested partially latent class analysis that integrates the results 
for each case from blood culture, NP/OP PCR, whole blood PCR 
for pneumococcus and induced sputum culture for M. tuberculosis. 
The PIA also integrates test results from controls to account for 
imperfect test specificity of NP/OP PCR and whole blood PCR. 
Blood culture results (excluding contaminants) and M. tuberculosis 
results were assumed to be 100% specific (ie, the etiology for a 
case was attributed 100% to the pathogen that was detected in their 
blood by culture).
The PIA accounts for imperfect sensitivity of each test/
pathogen measurement by using a priori estimates of their sensi-
tivity (ie, estimates regarding the plausibility range of sensitivity 
which varied by the laboratory test method and pathogen) (see 
Supplemental Digital Content 3, http://links.lww.com/INF/D998). 
Sensitivity of blood culture was reduced if blood volume was low 
(<1.5 mL) or if antibiotics were administered before specimen col-
lection. Sensitivity of NP/OP PCR for S. pneumoniae and H. influ-
enzae was reduced if antibiotics were administered before speci-
men collection.
As a Bayesian analysis, both the list of pathogens and their 
starting “prior” etiologic fraction values were specified a priori, 
which favored no pathogen over another (ie, “uniform” priors). The 
pathogens selected for inclusion in the analysis included any non-
contaminant bacteria detected by culture in blood at any of the 9 
PERCH sites, regardless of whether it was observed at The Gambia 
site specifically, M. tuberculosis, and all of the multiplex quantita-
tive PCR pathogens except those considered invalid because of poor 
assay specificity (Klebsiella pneumoniae31 and Moraxella catarrh-
alis). A category called “Pathogens Not Otherwise Specified” was 
also included to estimate the fraction of pneumonia caused by path-
ogens not tested for or not observed. A child negative for all patho-
gens would still be assigned an etiology, which would be either one 
of the explicitly estimated pathogens (implying a “false negative,” 
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accounting for imperfect sensitivity of certain measurements) or 
not otherwise specified. The model assumes that each child’s pneu-
monia was caused by a single pathogen. The model assumes that 
each child’s pneumonia was caused by a single pathogen.
All analyses were adjusted for age (<1 vs. ≥1 year) to 
account for differences in pathogen prevalences by this factor. For 
results stratified by case clinical data (such as by CXR positivity, 
severity and so on), the test results from all controls were used. 
However, for analyses stratified by age, only data from controls rep-
resentative of that age group were used.
The PIA estimated both the individual and population-level 
etiology probability distributions, each summing to 100% across 
pathogens where each pathogen has a probability ranging from 
0% to 100%. The population-level etiologic fraction estimate for 
each pathogen was approximately the average of the individual 
case probabilities and was provided with a 95% credible interval 
(95% CI), the Bayesian analog of the confidence interval. Primary 
analyses focused on CXR-positive HIV-negative cases. Descrip-
tive statistical analyses were performed using SAS 9.3 (SAS 
Institute, Cary, NC); the PIA was performed using the BAKER 
R package (https://github.com/zhenkewu/baker), R Statistical 
Software 3.3.1 (The R Development Core Team, Vienna, Austria), 
and Bayesian inference software JAGS 4.2.0 (http://mcmc-jags.
sourceforge.net/).
Ethics
Bioethical considerations in the PERCH project have been 
described in detail previously.32 We obtained written informed con-
sent for participation in the study from parents or legal guardians 
of cases and controls. The study was approved by The Gambian 
Government-Medical Research Council Joint Ethics Committee 
and the Institutional Review Board of the Johns Hopkins Bloomb-
erg School of Public Health (SCC/EC1062, 3075).
RESULTS
Study Participants
A total of 638 WHO-defined severe and very severe pneu-
monia cases (544 [85%] severe and 94 [15%] very severe), 286 
(45%) of which were CXR-positive and HIV-negative and 654 
community controls were available for analysis (Fig. 1 and Sup-
plementary Digital Content 4, http://links.lww.com/INF/D999). 
Of those eligible to participate, 85% were enrolled in the study. 
Seven (1%) cases were HIV-positive and excluded from subse-
quent analyses.
Demographic and clinical characteristics of the study 
groups are shown in Table 1. The majority (62.9%) of cases were 
under 1 year of age. Ten percent of cases had antibiotic exposure 
before admission and enrollment. Moderate (weight-for-age z 
score: −2 to −3) or severe (weight-for-age z score: <−3) malnutri-
tion was present in 30% of all cases, 34% of CXR-positive cases 
and 46% of all very severe cases, and 54% of CXR-positive very 
severe cases. Half (50.6%) of all cases enrolled had a normal CXR, 
16% had consolidation (WHO PEP criteria) and 29% had WHO 
“other infiltrates.” Hypoxemia was present in 8% of all cases and 
12% of CXR-positive cases. Four percent of all cases and 6% of 
CXR-positive cases died in hospital or within 30 days of admission 
FIGURE 1. Participant enrollment flow diagram. A: Cases. B: Controls. The number of controls selected for screening is 
accurate to ±0.3%, reflecting minor inconsistency of recorded numbers.
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TABLE 1. Demographic and Clinical Characteristics of HIV-uninfected Cases and Controls
All Cases CXR+ Cases Controls
CXR+ Severe  
Cases
CXR+ Very  
Severe Cases
All 631 286 654 247 39
Age      
  Median age (mo) (IQR) 8 (3, 18) 9 (4, 17) 11 (5, 22) 8 (4, 18) 10 (5, 16)
  1–5 mo 253 (40.1) 106 (37.1) 199 (30.4) 94 (38.1) 12 (30.8)
  6–11 mo 144 (22.8) 71 (24.8) 133 (20.3) 60 (24.3) 11 (28.2)
  12–23 mo 136 (21.6) 70 (24.5) 181 (27.7) 59 (23.9) 11 (28.2)
  24–59 mo 98 (15.5) 39 (13.6) 141 (21.6) 34 (13.8) 5 (12.8)
Ethnicity      
  Wollof 7 (1.1) 3 (1.1) 2 (0.3) 3 (1.2) 0 (0.0)
  Mandinka 179 (28.9) 77 (27.3) 165 (25.5) 65 (26.6) 12 (31.6)
  Serahule 286 (46.2) 128 (45.4) 258 (39.9) 112 (45.9) 16 (42.1)
  Fula 146 (23.6) 74 (26.2) 213 (33.0) 64 (26.2) 10 (26.3)
  Other 1 (0.2) 0 (0.0) 8 (1.2) 0 (0.0) 0 (0.0)
Female 243 (38.5) 108 (37.8) 308 (47.1) 90 (36.4) 18 (46.2)
Season of enrollment      
  Rainy (June–October) 297 (47.1) 140 (49) 279 (42.7) 125 (50.6) 15 (38.5)
  Dry (November–May) 334 (52.9) 146 (51.0) 375 (57.3) 122 (49.4) 24 (61.5)
Respiratory tract illnessa — — 159 (24.3) — —
Malaria slide positive 11 (1.9) 3 (1.2) 7 (1.1) 3 (1.3) 0 (0.0)
Pentavalent fully vaccinated for ageb      
  <1 y old 213 (55.6) 96 (56.1) 218 (67.1) 87 (58.4) 9 (40.9)
  ≥1 y old 202 (93.1) 97 (94.2) 271 (92.8) 83 (94.3) 14 (93.3)
PCV fully vaccinated for ageb      
  <1 y old 211 (55.1) 95 (55.6) 214 (66.0) 86 (57.7) 9 (40.9)
  ≥1 y old 192 (88.9) 94 (91.3) 232 (80.0) 81 (92.1) 13 (86.7)
Measles fully vaccinatedc 238 (90.8) 119 (91.5) 303 (89.9) 103 (93.6) 16 (80.0)
Weight-for-age (WHO) z scores      
  >−2 z scores 444 (70.4) 188 (65.7) 531 (81.8) 170 (68.8) 18 (46.2)
  −3 ≤ z scores ≤ −2 121 (19.2) 64 (22.4) 83 (12.8) 52 (21.1) 12 (30.8)
  <−3 z scores 66 (10.5) 34 (11.9) 35 (5.4) 25 (10.1) 9 (23.1)
Weight-for-height (WHO) z scores      
  >−2 z scores 459 (73.0) 201 (70.5) 541 (84.3) 179 (72.8) 22 (56.4)
  −3 ≤ z scores ≤ −2 114 (18.1) 55 (19.3) 73 (11.4) 46 (18.7) 9 (23.1)
  <−3 z scores 56 (8.9) 29 (10.2) 28 (4.4) 21 (8.5) 8 (20.5)
Height-for-age (WHO) z scores      
  >−2 z scores 515 (81.6) 234 (81.8) 538 (82.9) 203 (82.2) 31 (79.5)
  −3 ≤ z scores ≤ −2 70 (11.1) 34 (11.9) 80 (12.3) 29 (11.7) 5 (12.8)
  <−3 z scores 46 (7.3) 18 (6.3) 31 (4.8) 15 (6.1) 3 (7.7)
Antibiotic pretreatment prior to specimen 
collectiond
59 (9.5) 30 (10.6) 1 (0.2) 24 (9.8) 6 (15.4)
Serum antibiotic activity 42 (7.3) 20 (7.6) 1 (0.2) 16 (7.0) 4 (11.4)
CXR result      
  Any abnormality 286 (45.3) 286 (100) — 247 (100) 39 (100)
   Any consolidation 101 (16.1) 101 (35.3) — 80 (32.4) 21 (53.8)
   Other infiltrate only 185 (29.4) 185 (64.7) — 167 (67.6) 18 (46.2)
  Normal 318 (50.6) 0 (0.0) — 0 (0.0) 0 (0.0)
  Uninterpretable 25 (4.0) 0 (0.0) — 0 (0.0) 0 (0.0)
Hypoxemiae 49 (7.8) 33 (11.5) — 23 (9.3) 10 (25.6)
Tachypneaf 547 (86.7) 260 (90.9) — 227 (91.9) 33 (84.6)
Tachycardiag 342 (54.3) 159 (55.8) — 138 (56.1) 21 (53.8)
Very severe pneumoniah 94 (14.9) 39 (13.6) — 0 (0.0) 39 (100)
Danger signs      
Head nodding 28 (4.4) 17 (5.9) — 0 (0.0) 17 (43.6)
Central cyanosis 4 (0.6) 4 (1.4) — 0 (0.0) 4 (10.3)
Convulsionsi 29 (4.6) 5 (1.7) — 0 (0.0) 5 (12.8)
Lethargyj 55 (8.7) 23 (8) — 0 (0.0) 23 (59.0)
Unable feed 17 (2.7) 6 (2.1) — 0 (0.0) 6 (15.4)
Vomiting 8 (1.3) 2 (0.7) — 0 (0.0) 2 (5.1)
Crackles 486 (77.1) 231 (81.1) — 200 (81.3) 31 (79.5)
Wheeze on auscultation 198 (31.5) 84 (29.6) — 76 (31.0) 8 (20.5)
Grunting 50 (7.9) 26 (9.1) — 16 (6.5) 10 (25.6)
Nasal flaring 332 (52.6) 161 (56.3) — 133 (53.8) 28 (71.8)
Elevated temperature (≥38°C) 205 (32.5) 117 (40.9) — 98 (39.7) 19 (48.7)
Leukocytosisk 196 (43.1) 100 (49.8) — 81 (45.8) 19 (79.2)
CRP ≥ 40 mg/L 132 (34.5) 86 (48.9) — 73 (47.7) 13 (56.5)
Severe anemia (0–7.5 g/dL) 33 (7.3) 14 (7.0) — 9 (5.1) 5 (20.8)
Duration of illnessl      
  Median duration of illness (d)l (IQR) 3 (2, 3) 3 (2, 4) — 3 (2, 4) 3 (2, 5)
  0–2 d 256 (40.6) 112 (39.2) — 98 (39.7) 14 (35.9)
  3–5 d 332 (52.6) 149 (52.1) — 130 (52.6) 19 (48.7)
  >5 d 43 (6.8) 25 (8.7) — 19 (7.7) 6 (15.4)
(Continued)
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(following discharge). Among controls ≥1 year of age, 93% were 
fully vaccinated for age against H. influenzae and 80% of controls 
were fully vaccinated for age against S. pneumoniae.
Positive blood cultures were observed in 14 (5%) of CXR-
positive cases: 7 (50%) were S. pneumoniae (n = 2 PCV13 serotypes 
and n = 5 non-PCV13 serotypes), 2 were H. influenzae non-type 
b and the remaining were single occurrences of other pathogens 
(Table 2). Lung aspirates were available from 21 CXR-positive 
cases with S. pneumoniae, M. catarrhalis and H. influenzae being 
the most commonly detected pathogens, while the single pleural 
aspirate sample cultured Staphylococcus aureus (Table 2). There 
were 6/13 (46%) confirmed pneumococcal pneumonia cases with 
vaccine-type serotypes (n = 3 ST1 and n = 1 each ST5, ST19F and 
ST6A) (Supplemental Digital Content 5, http://links.lww.com/INF/
D1000). M. tuberculosis was cultured from the induced sputum of 
7 (2.7%) CXR-positive cases (Table 2). The prevalence and ORs 
for pathogens detected on NP/OP in CXR-positive cases and con-
trols are shown in supplemental digital content 6, http://links.lww.
com/INF/E2; 7, http://links.lww.com/INF/E3 and 8, http://links.
lww.com/INF/E4. Positivity was significantly associated with case 
status for 6 pathogens (S. pneumoniae [threshold], HMPV A/B, 
influenza A, parainfluenza 1 and 3, CMV and respiratory syncytial 
virus [RSV]).
Seasonality
The frequency of all case admissions and CXR-positive 
admissions was markedly seasonal, with a 3- to 4-fold higher peak 
in the latter part of the calendar year (Fig. 2A). The peaks in CXR-
positive cases corresponded closely with an increased prevalence 
of NP/OP PCR positivity for respiratory viruses, notably RSV and 
parainfluenza (Fig. 2B).
Etiology
Among CXR-positive cases RSV (37.3%) and S. pneumo-
niae (13.0%) were the leading causes, followed by parainfluenza 
viruses (9.2%), M. tuberculosis (8.3%) and H. influenzae (4.7%), 
with viruses accounting for 58% of cases and bacteria 28% (Fig. 3, 
Supplemental Digital Content 9, http://links.lww.com/INF/E5). 
The leading causes of severe (but not very severe) CXR-positive 
pneumonia were, similarly, RSV and parainfluenza viruses, with 
71% of cases estimated to have a viral etiology (Fig. 4A, Sup-
plemental Digital Content 10, http://links.lww.com/INF/E6). In 
contrast, in CXR-positive very severe pneumonia cases, bacterial 
causes dominated (76.8%) with S. pneumoniae (41.2%) being the 
leading cause (Fig. 4A and Supplemental Digital Content 10, http://
links.lww.com/INF/E6).
In those with CXR-positive severe or very severe pneumo-
nia, the leading cause in older children (1 or more years of age) was 
S. pneumoniae followed by RSV (Fig. 4B and Supplemental Digital 
Content 11, http://links.lww.com/INF/E7), while the leading cause 
in younger infants under 1 year of age was RSV (49.9%) followed 
by M. tuberculosis (10.3%), S. pneumoniae (9.4%) and parainflu-
enza (8.4%); similar findings by age were seen when restricting to 
severe pneumonia cases (Supplemental Digital Content 12, http://
links.lww.com/INF/E8). Findings from CXR-positive cases were 
similar to those from all cases, which showed that RSV and parain-
fluenza dominated, accounting for half (49.8%) of pneumonia etiol-
ogies as estimated by the PIA method, with viral causes responsible 
for 66% overall, bacterial causes 26.2% and M. tuberculosis 5.1% 
(Supplemental Digital Content 9, http://links.lww.com/INF/E5 and 
13, http://links.lww.com/INF/E9).
Etiology differed by malnutrition status, with bacterial 
infection being more prevalent in acutely malnourished children 
(53.7% in those with a weight-for-height z-score below −2 vs. 
29.1% in those with a weight-for-height z-score above than −2); 
Median duration of hospitalization (d) (IQR) 3 (2, 4) 3 (2, 4) — 3 (2, 4) 4 (2, 5)
Duration of hospitalization      
  0–2 d 15 (2.4) 9 (3.2) — 84 (34.3) 10 (25.6)
  3–5 d 554 (88.5) 239 (84.2) — 134 (54.7) 20 (51.3)
  >5 d 57 (9.1) 36 (12.7) — 27 (11.0) 9 (23.1)
Died in hospital or within 30 d of admission 27 (4.3) 16 (5.6) — 5 (2.0) 11 (28.2)
  Died in-hospital 21 (3.3) 12 (4.2) — 2 (0.8) 10 (25.6)
  Died postdischarge, within 30 d of 
admissionm
6 (1.0) 4 (1.5) — 3 (1.2) 1 (3.5)
Missing 30-d vital statusm 6 (1.0) 2 (0.7) — 1 (0.4) 1 (3.5)
IQR indicates interquartile range.
aControls were considered to have respiratory tract illness (RTI) if they had (1) cough (observed or reported) or runny nose (reported) or (2) one of the following: ear discharge 
(reported), wheeze (reported) or difficulty breathing (reported), in the presence of sore throat (reported) or fever (observed temperature ≥38.0°C or reported fever in the past 48 hours).
bFor children <1 year, defined as received at least one dose and up-to-date for age based on the child’s age at enrollment, doses received and country schedule (allowing 4-week 
window each for dose). For children > 1 year, defined as 3+ doses.
cAt least 1 dose, restricted to children >10 months.
dDefined as serum bioassay positive (cases and controls), antibiotics administered at the referral facility, or antibiotic administration prior to whole-blood specimen collection at 
the study facility (cases only).
eHypoxemia defined as oxygen saturation <92%, or on supplemental oxygen if a room air oxygen saturation reading was not available. A room air oxygen saturation reading was 
available from 616 (97.6%) of children.
fTachypnea defined as ≥60 breaths per minute (<2 months), ≥50 breaths per minute (2–11 months) and ≥40 breaths per minute (12–59 months).
gTachycardia defined as >160 beats per minute (bpm) (<11 months), >150 bpm (12–35 months) and >140 bpm (36–59 months).
hVery severe pneumonia defined as cough or difficulty breathing, and at least one of the following: central cyanosis, difficulty breast-feeding/drinking, vomiting everything, con-
vulsions, lethargy, unconsciousness or head nodding.
iMultiple or prolonged convulsions (≥15 min).
jLethargic or unresponsive (responds to voice or pain, unresponsive or pharmacologically sedated).
kLeukocytosis count defined as >15 × 109 cells/L for children 1–11 months and >13 × 109 cells/L for children 12–59 months.
lDefined as maximum days of reported symptoms for any of the following: cough, wheeze, fever or difficulty breathing.
mRestricted to those children discharged alive.
TABLE 1. (Continued.)
All Cases CXR+ Cases Controls
CXR+ Severe  
Cases
CXR+ Very  
Severe Cases
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specifically, RSV was less prevalent in the undernourished (19.8% 
vs. 37.0%), while H. influenzae (13.7% vs. 3.1%) and Enterobacte-
riaceae (4.2% vs. 0.4%) were more prevalent in the undernourished 
(data not shown). There was one blood culture positive for Candida 
species in a severely chronically malnourished child 20 months of 
age. This one positive translated into an etiology fraction of 4.0% 
for Candida species among CXR-positive cases, with sensitivity 
analyses around the sensitivity of blood culture for Candida indi-
cating that it is unlikely to be less than 2%.
In-hospital case fatality rates were 3.3% overall, 4.2% in 
CXR-positive cases, 19.1% in all very severe cases and 25.6% in 
very severe CXR-positive cases. Among the 21 deaths, bacterial 
causes were prominent (8 normally sterile sample-confirmed; Sup-
plemental Digital Content 14, http://links.lww.com/INF/E10).
DISCUSSION
This study showed that the leading causes of severe pneu-
monia in young children in The Gambia site were RSV, S. pneumo-
niae, parainfluenza and M. tuberculosis, and in very severe cases, 
bacterial causes predominated, notably S. pneumoniae. RSV was 
the leading pathogen in the PERCH study overall, and the find-
ings in The Gambia site reinforce its importance in all subgroups, 
and notably in the youngest children.29 The priority of develop-
ing interventions to reduce the RSV-pneumonia burden is high, 
as previously discussed.29 The Gambia had a higher prevalence of 
parainfluenza than other PERCH study sites, the result of more than 
1 outbreak during the study period and a reminder that epidemic 
pathogens are an ever-present threat.
TABLE 2. Detection of Organisms in Case-only Specimens, by Specimen and Test
Organism Test All Cases CXR+ Cases
A. Blood N = 615 N = 279
 Anya Culture 26 (4.2) 14 (5.0)
 Streptococcus pneumoniae Culture 10 (1.6) 7 (2.5)
   S. pneumoniae VT (PCV13) Culture 2 (0.3) 2 (0.7)
   S. pneumoniae non-VT (PCV13) Culture 8 (1.3) 5 (1.8)
 Haemophilus influenzae Culture 3 (0.5) 2 (0.7)
  H. influenzae type b Culture 1 (0.2) 0 (0.0)
  H. influenzae non-type b Culture 2 (0.3) 2 (0.7)
 Staphylococcus aureus Culture 3 (0.5) 1 (0.4)
 Salmonella spp.b Culture 2 (0.3) 1 (0.4)
 Other nonfermentative Gram-negative rodsc Culture 1 (0.2) 0 (0.0)
 Enterobacteriaceaed Culture 4 (0.7) 1 (0.4)
 Neisseria meningitides Culture 2 (0.3) 1 (0.4)
 Candida sp. Culture 1 (0.2) 1 (0.4)
 Mixede Culture 1 (0.2) 0 (0.0)
 Contaminants Culture 43 (7.0) 24 (8.6)
B. Lung aspiratef    
N = 22 N = 21
 Any Culture 5 (22.7) 5 (23.8)
 PCR 6 (35.3) 6 (35.3)
 Culture or PCR 8 (36.4) 8 (38.1)
 S. pneumoniae Culture 5 (22.7) 5 (23.8)
 PCR 5 (29.4) 5 (29.4)
 Culture or PCR 7 (31.8) 7 (33.3)
    S. pneumoniae VT (PCV13)g Culture or PCR 4 (18.2) 4 (19.2)
    S. pneumoniae non-VT (PCV13)g Culture or PCR 2 (9.1) 2 (9.5)
 Moraxella Catarrhalis Culture 0 (0.0) 0 (0.0)
 PCR 3 (17.6) 3 (17.6)
 Culture or PCR 3 (13.6) 3 (14.3)
 H. influenzaeh Culture 1 (4.5) 1 (4.8)
 PCR 2 (11.8) 2 (11.8)
 Culture or PCR 2 (9.1) 2 (9.5)
C. Pleural fluidf,i    
N = 1 N = 1
 Any Culture 1 (100) 1 (100)
 S. aureus Culture 1 (100) 1 (100)
D. Induced sputum    
N = 575 N = 255
 Mycobacterium tuberculosis Culture 7 (1.2) 7 (2.7)
aExcludes contaminants.
bNontyphoidal Salmonella species (N = 2).
cAcinetobacter species (N = 1).
dEnterobacter cloacae (N = 1); Escherichia coli (N = 3); Klebsiella pneumoniae (N = 1).
eE. coli and K. pneumoniae (N = 1).
fRestricted to specimens obtained within 3 days of admission and those pathogens determined by the clinical review team to be noncontaminants. 
Data reflect any positivity; some children were positive for multiple organisms on lung aspirate. 22/22 cases had lung aspirate culture results avail-
able, and 17/22 had lung aspirate PCR results available. Denominator for “Culture or PCR” rows reflects children with either culture or PCR (N = 22).
gTwo cases were positive for S. pneumoniae by lung aspirate PCR only so no lung aspirate serotype data available. For one of these cases, the sero-
type detected on induced sputum (ST = 1) was assumed to the ST that would have been detected on lung aspirate because it is rarely detected in healthy 
children. One case was positive for an S. pneumoniae non-PCV13 type serotype on both blood culture and lung aspirate culture.
hOne case was positive for H. influenzae by culture and PCR; serotyping results for culture isolate were missing but were H. influenzae non-type b 
by PCR. One case positive for H. influenzae type b by PCR.
iOne case with a pleural fluid specimen was missing pleural fluid PCR results.
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FIGURE 2. Enrollment and NP/OP PCR positivity by month of study. A: PERCH enrollment by month, all cases, controls, 
and CXR+ cases. CXR+ defined as consolidation and/or other infiltrate on chest radiograph (subset of the all case groups).B: 
Enrollment and NP/OP PCR positivity for select viruses by month, CXR+ cases. CXR+ defined as consolidation and/or other 
infiltrate on chest radiograph. HMPV, human metapneumovirus A/B; NP/OP, nasopharyngeal/oropharyngeal; Para 1, 
parainfluenza virus types 1; Para 3, para, parainfluenza virus types 3; RSV, respiratory syncytial virus A/B.
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The Upper River Region study site in The Gambia was 
selected for participation in the PERCH Study because of its rural 
West African location. It complements the urban West African site 
in Mali, the urban East African site in Zambia, the rural East Afri-
can site in Kenya and the Asian sites in Thailand and Bangladesh. 
It is notable that The Gambia has a low gross domestic product per 
capita, a high child mortality rate, seasonal malaria transmission 
and a low HIV infection prevalence.10,11
While viral causes such as RSV and parainfluenza pre-
dominated overall, pneumococcus was the leading pathogen 
among the very severe pneumonia cases, even in the presence 
of high PCV coverage, and bacterial causes accounted for 
three-quarters of very severe cases. The continued importance 
of bacterial pathogens in very severe cases and in deaths con-
tinues to support the priority of prompt treatment of cases with 
appropriate antibiotics in countries like The Gambia and the 
continued development and increased use of bacterial-target 
vaccines.
In a previous pre-PCV (but Hib vaccine era) study of 
lung aspirate samples from children with CXR-positive severe 
FIGURE 3. Integrated etiology results, CXR+ cases. Other Strep includes Streptococcus pyogenes and Enterococcus faecium. 
NFGNR includes Acinetobacter species and Pseudomonas species. Enterobacteriaceae includes Escherichia coli, Enterobacter 
species and Klebsiella species, excluding mixed Gram-negative rods. CXR+ defined as consolidation and/or other infiltrate on 
chest radiograph. Bacterial summary excludes Mtb. Pathogens that were estimated at the subspecies level but grouped to 
the species level for display include Parainfluenza virus type 1, 2, 3 and 4; S. pneumoniae PCV 13 and S. pneumoniae non-PCV 
13 types; H. influenzae type b and H. influenzae non-type b; and influenza A, B and C. Etiologic fraction estimates, including 
subspecies and serotype disaggregation (eg, PCV-13 type and non-PCV-13 type), are given in Supplemental Digital Content 
6, http://links.lww.com/INF/E2. Line represents the 95% credible interval. The size of the symbol is scaled on the basis of 
the ratio of the estimated etiologic fraction to its standard error. Of 2 identical etiologic fraction estimates, the estimate 
associated with a larger symbol is more informed by the data than the priors. Adeno indicates adenovirus; B. pert, Bordetella 
pertussis; Boca, human bocavirus; C. pneu, Chlamydophila pneumoniae; Cand sp., Candida species; CMV, cytomegalovirus; 
Entrb, enterobacteriaceae; Flu, influenza virus A, B and C; H. inf, Haemophilus influenzae; HCoV, coronavirus; HMPV, human 
metapneumovirus A/B; Legio, Legionella species; M. cat, Moraxella catarrhalis; M. pneu, Mycoplasma pneumoniae; Mtb, 
Mycobacterium tuberculosis; NFGNR, nonfermentative Gram-negative rods; N. men, Neisseria meningitidis; NoS, not otherwise 
specified (ie, pathogens not tested for); P. jirov, P. jirovecii; Para, parainfluenza virus types 1, 2, 3 and 4; PV/EV, parechovirus/
enterovirus; Rhino, human rhinovirus; RSV, respiratory syncytial virus A/B; S. aur, Staphylococcus aureus; S. pneu, Streptococcus 
pneumoniae; Salm sp, Salmonella species.
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pneumonia, bacterial causes dominated, led by S. pneumoniae and 
followed by H. influenzae, mostly nontypeable.33 This is consistent 
with previous studies of severe pneumonia in The Gambia with the 
exception that pre-Hib vaccination most H. influenzae was type b. 
The H. influenzae identified in the current study was mostly non-
type b, which is consistent with the very low rate of Hib infection 
seen in the Gambian surveillance studies.34 Of the confirmed pneu-
mococcal pneumonia cases, 46% were vaccine-type; while this 
study was not designed to assess vaccine effectiveness the finding 
reinforces the importance of ongoing surveillance to monitor this.
It is notable that tuberculosis played an important role in pneu-
monia etiology in this study. Previous studies of radiologic childhood 
pneumonia in The Gambia in the pre-PCV and pre-Hib vaccine era 
identified tuberculosis in 1%–4% of cases. In PERCH, tuberculosis 
was responsible for an estimated 8.3% of CXR-positive pneumonia 
cases in The Gambia.35,36 Tuberculosis should be in clinicians’ minds, 
especially where it is prevalent and where children do not respond 
adequately to empirical treatment with standard antibiotics.37
This study highlights the importance of epidemic patho-
gens such as parainfluenza viruses, notably types 1 and 3, which 
featured strongly in The Gambia.29 Parainfluenza epidemics occur 
periodically and can cause considerable morbidity in children, typi-
cally lower respiratory tract infections in infants and laryngotra-
cheobronchitis (croup) in preschoolers.38,39 It is notable that the 
burden of parainfluenza-associated pneumonia in The Gambia was 
not the result of a single outbreak but several from more than 1 
serotype. While efforts toward the development and application of 
respiratory viral vaccines have focused historically on measles and 
influenza, and more recently RSV, future efforts may need to add 
parainfluenza.40
Severe childhood pneumonia in The Gambia occurs year-
round; nevertheless, important seasonal differences were observed 
in pneumonia incidence and etiology, with the “pneumonia season” 
typically occurring between September and November annually, 
which coincides with the latter part of the hot humid rainy season. 
In the PERCH study, these peaks coincided with outbreaks of RSV 
(which occur annually).
This study had the strengths of a carefully designed and 
executed case-control study, the characteristics of which have been 
well described.20–23,27 Standardization of methods and sufficient 
power at The Gambian site lend weight to the findings reported 
here. Eighty-five percent of all admissions occurred during enroll-
ment hours; however, because overnight admissions were excluded, 
it is possible that enrollment bias against more severe or fatal cases 
presenting after hours may have resulted. There are, additionally, 
well-described limitations of any case-control study, even a large 
one, and the scarcity of gold-standard specimens, such as lung and 
pleural aspirates, make a degree of caution in interpretation of the 
findings appropriate. There is also the limitation of the WHO diag-
nostic criteria, which are sensitive but not specific for pneumonia, 
meaning that some cases without pneumonia, for instance with 
bronchiolitis or sepsis, will be categorized as pneumonia. Never-
theless, the similarity of results between those with CXR-positive 
pneumonia criteria and those with WHO clinically defined pneu-
monia argues against important bias resulting from case definitions.
Although PERCH relied on multiple samples (blood, NP/OP 
swabs, induced sputum) to estimate etiology, they were not taken 
directly from the site of infection (the lung), which is true for most 
etiology studies. Nevertheless, these specimens do have diagnostic 
potential, as demonstrated by association with case status within 
the PERCH analysis, and indeed in standard clinical practice, such 
FIGURE 4. Integrated etiology results, CXR+ cases, by (A) pneumonia severity and (B) age, selected pathogens. CXR+ 
defined as consolidation and/or other infiltrate on chest radiograph. Bacterial summary excludes Mtb. Very severe 
pneumonia defined as cough or difficulty breathing, and at least one of the following: central cyanosis, difficulty breast-
feeding/drinking, vomiting everything, convulsions, lethargy, unconsciousness or head nodding. Sample sizes: CXR+ severe, 
N = 247; CXR+ very severe, N = 39. CXR+ <1 year, N = 177; CXR+ ≥1 year, N = 109. Pathogens that were estimated at the 
subspecies level but grouped to the species level for display include Parainfluenza virus types 1, 2, 3 and 4; S. pneumoniae 
PCV 10 and S. pneumoniae non-PCV 10 types; and H. influenzae type b and H. influenzae non-type b. Line represents the 
95% credible interval. The size of the symbol is scaled based on the ratio of the estimated etiologic fraction to its standard 
error. Of two identical etiologic fraction estimates, the estimate associated with a larger symbol is more informed by the 
data than the priors. H. inf indicates Haemophilus influenzae; HMPV, human metapneumovirus A/B; Mtb, Mycobacterium 
tuberculosis; NoS, not otherwise specified (ie, pathogens not tested for); Parainfluenza virus types 1, 2, 3 and 4; Respiratory 
syncytial virus A/B; S. pneu, Streptococcus pneumoniae.
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as NP/OP PCR results for pertussis and RSV or induced sputum 
for tuberculosis. Unfortunately, there is no fool-proof method for 
distinguishing chronic carriage from newly acquired exposure or 
infection in a case control study; however, using quantitative PCR 
and applying density thresholds that were associated with detec-
tion in the blood improved the value of the data. The PIA model 
assumes that each case’s pneumonia episode is caused by a single 
pathogen, and it does not attempt to identify or quantify pathogen 
combinations. While we acknowledge that copathogen causes will 
result in an underestimate of any single cause, exploratory analy-
ses do not support a large underestimate (data not shown). Last, it 
is important to acknowledge that, within the broad methodologic 
challenges facing pneumonia etiology studies, the PIA model takes 
an important step forward in accounting for and mitigating those 
limitations, and this is an important contribution the PERCH study 
makes to the field.
CONCLUSIONS
At The Gambian site of the PERCH study, viral causes pre-
dominated overall, as they did in other sites, with RSV being the 
leading cause. S. pneumoniae was the second most prevalent cause 
in The Gambia, followed by Parainfluenza, the result of several out-
breaks during the study period, and a reminder of the importance of 
epidemic pathogens. Tuberculosis was also a notable cause, high-
lighting that the tuberculosis global pandemic continues to impact 
children. Despite the preponderance of viral causes overall, very 
severe cases were predominantly bacterial, with S. pneumoniae 
most important despite high coverage with PCV immunization in 
the population. These findings support the continued emphasis on 
appropriate case management of severe pneumonia and also ongo-
ing efforts to prevent disease by developing new vaccines, notably 
to RSV, and optimizing access to existing vaccines.
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